SCHEDULE 13G: TCG Crossover Entities Disclose 9.99% Stake in RAPT Therapeutics

TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu have jointly disclosed a beneficial ownership of 9.99% in RAPT Therapeutics, Inc., totaling 13,193,110 shares.

Summary

• TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu (collectively, the "Reporting Persons") have filed a Schedule 13G disclosing their beneficial ownership in RAPT Therapeutics, Inc.
• The Reporting Persons collectively beneficially own 13,193,110 shares of RAPT Therapeutics' Common Stock.
• This ownership represents 9.99% of the total outstanding Common Stock of RAPT Therapeutics.
• The reported shares consist of 13,135,260 shares of Common Stock and 57,850 shares of Common Stock subject to pre-funded warrants that are exercisable within 60 days.
• An additional 10,334,890 shares subject to pre-funded warrants are excluded from this total because they are not exercisable within 60 days due to a 9.99% beneficial ownership limitation.
• The beneficial ownership percentage is calculated based on 132,064,678 shares of Common Stock, which includes 132,006,828 shares outstanding as of December 27, 2024, plus the 57,850 exercisable warrant shares.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of RAPT Therapeutics.

Sentiment

Score: 7

Explanation: The disclosure of a significant, passive stake by a reputable institutional investor like TCG Crossover is generally viewed positively by the market, as it signals confidence in the company's prospects without implying an activist agenda.

Positives

• A significant institutional investor, TCG Crossover, has taken a substantial 9.99% stake in RAPT Therapeutics, potentially signaling confidence in the company's future prospects.
• The investment is stated to be passive, not intended to influence control, which suggests a long-term investment perspective rather than an activist one, potentially reducing perceived governance risks.

Risks

• The beneficial ownership limitation on pre-funded warrants means that TCG Crossover cannot immediately exercise all their warrants if doing so would push their ownership above 9.99%, which could limit their flexibility or potential upside from those specific warrants.

Future Outlook

The filing itself does not provide forward-looking statements or guidance from RAPT Therapeutics. It solely reports a significant ownership stake by TCG Crossover entities, indicating their current investment position.

Industry Context

This filing indicates a significant investment by a crossover fund (TCG Crossover) in a biotechnology company, RAPT Therapeutics. Crossover funds typically invest in private companies that are nearing or have recently completed an IPO, or in public companies with high growth potential, often in the life sciences sector. This suggests TCG Crossover sees value or future potential in RAPT Therapeutics' pipeline or technology, aligning with broader trends of institutional investment in innovative biotech firms.

Comparison to Industry Standards

• This document is a beneficial ownership report and does not contain financial or operational results that can be directly compared to industry standards or specific comparable companies/projects. It merely discloses an investment stake.
• A 9.99% stake is a substantial position for an institutional investor in a publicly traded company, indicating a high level of conviction in RAPT Therapeutics' value proposition.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake could increase investor confidence and potentially positively influence share price.
• Company Management: The passive nature of the investment suggests TCG Crossover is not seeking to influence management or corporate strategy, allowing current management to continue their plans.

Key Dates

Recommendation

Keywords

RAPT Therapeutics, TCG Crossover Fund II, TCG Crossover GP II, Chen Yu, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Biotechnology, Pharmaceuticals, Investment, Institutional Investor